7 results about "Serum amyloid P" patented technology

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination capable of simultaneously recognizing equine and feline serum amyloid A (SAA) and its application. The monoclonal antibody combination comprises 6E10 and 5A6. The CDR sequences of the heavy and light chain variable regions of 6E10 are shown in SEQ ID NO. 1-6, and the CDR sequences of the heavy and light chain variable regions of 5A6 are shown in SEQ ID NO. 7-12. This antibody combination can highly specifically recognize and bind to recombinant equine and feline SAA proteins, achieving multiple uses with a single antibody and reducing raw material development and production costs. The colloidal gold test strip constructed based on this combination exhibits high specificity, high sensitivity, and a wide detection range, with no cross-reactivity. It is easy to operate and requires no complex instruments, providing a stable and reliable biorecognition tool for assessing and monitoring inflammation-related physiological states in animals.

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.

A serum amyloid protein A and C reactive protein joint detection kit comprises a kit body, a sliding rod, a movable seat, a lock sleeve, a positioning rod, a rotating sleeve, a main gear disc and a movable plate, the upper portion of the kit body is connected with a kit cover, the kit body is provided with a connecting block, the kit cover is provided with a connecting lug, the connecting lug is connected with the connecting block through a shaft rod, and the shaft rod is sequentially connected with the connecting lug and the connecting block. The kit is connected with the lock seat, the box cover is connected with the lock tongue, the lock tongue is matched with the lock seat, the lock tongue is connected with the lock seat, the upper part of the kit is provided with a fixing plate, the fixing plate is provided with a plurality of placing holes, the placing holes are matched with test tubes, the test tubes penetrate through the placing holes and are connected with the inner side of the rubber ring, and the outer side of the rubber ring is connected with the fixing plate.

The present disclosure relates to anti-SAA antibodies or fragments thereof, such as antibodies against human SAA1 or fragments thereof, that may be used in various therapeutic, prophylactic and diagnostic methods. The present antibodies or fragments thereof may be used to treat hematologic disorders such as acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome.

The invention relates to the technical field of biological medicine, in particular to a biomarker combination, a kit of the biomarker combination and application of the biomarker combination in diagnosis of acute Stanford B-type aortic dissection (ATBAD). The biomarker combination comprises serum amyloid protein A1 (SAA1), serum amyloid protein A2 (SAA2), C-reactive protein (CRP), neutrophil elastinase (ELANE), matrix metalloenzyme 9 (MMP9), nest protein 1 (NID1), mannose binding lectin 2 (LMAN2) and proprotein convertase subtilisin / kexin type 9 (PCSK9), and the biomarker combination can realize high-sensitivity and high-accuracy detection of ATBAD. And the anti-interference capability is excellent.

The invention relates to a serum amyloid A (SAA) protein mutant and a preparation method thereof. Specifically, the serum amyloid A protein mutant contains core amino acids selected from the following groups: (a) the first amino acid is A or G; (b) the fifth amino acid is A or G; and / or (c) the 8th amino acid is A; wherein the amino acid position number is based on the sequence represented by any one of SEQ ID NO: 1 and SEQ ID NO: 69 to SEQ ID NO: 73. According to the method, the yield of SAA protein is increased, the problem of endotoxin is avoided, and the difference of folding modes or immunogenicity when other systems are used for expressing protein is avoided.

The application discloses a single-domain antibody of serum amyloid protein SAA, a nucleotide sequence coding the single-domain antibody is shown as SEQ ID NO:1, and an amino acid sequence of the single-domain antibody is shown as SEQ ID NO:2. The single-domain antibody of serum amyloid protein SAA provided by the application shows excellent stability in a range from normal temperature to 50 DEG C, especially can be stored for a long time under the condition of normal temperature to 50 DEG C, obviously reduces the difficulty of antibody storage, and effectively saves the cost of storage and transportation.